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Introduction

Manual thrombus aspiration protocol
Manual thrombus aspiration was recommended. After the guide wire has crossed the lesion, thrombus aspiration was routinely performed in a totally occluded culprit vessel (Thrombolysis in Myocardial Infarction [TIMI] flow of 0). If pre-procedural TIMI flow 1 to 3 was observed, the aspiration judgement was based on the presence or absence of a large thrombus burden. If a large thrombus burden was visualized, manual thrombectomy was performed. Direct stenting was advised if a lesion with a small thrombus burden was present [6] . The most commonly used thrombus aspiration catheter was a 6F Thrombuster II (Kaneka, Japan).
Administration of GPI (Eptifibatide)
After arrival in the emergency department, patients received intravenous eptifibatide using a weight adjusted dose (a single intravenous bolus of 180 µg/kg followed by a continous infusion of 2.0 µg/kg/min up to 12-18 hours) as soon as primary PCI had been planned. Additional intracoronary eptifibatide was given at the operator's discretion.
Antiplatelet and anticoagulant regimen
All patients were pre-treated with 160-320 mg acetylsalicylic acid and 600 mg clopidogrel orally before primary PCI, followed by daily administration of 75 mg clopidogrel planned for at least 1 year after discharge and 80-100 mg acetylsalicylic acid indefinitely. Before PCI, all patients received an intravenous bolus of unfractionated heparin (50-60 IU/kg).
Microvascular perfusion evaluation
Diagnostic modalities that were used to evaluate microvascular perfusion were the angiographic measurement of coronary flow and tissue perfusion (TIMI flow and myocardial blush grading) in all patients following primary PCI, applying the following definitions: • TIMI flow grading: TIMI flow grade 0: absent antegrade flow; TIMI flow grade 1: partial contrast penetration beyond an occlusion with incomplete distal filling; TIMI flow grade 2: patent epicardial artery with opacification of the entire distal artery also contrast filling or washout is delayed; TIMI flow grade 3: patent epicardial artery with normal flow [7] . • Myocardial blush grading (MBG): MBG 0: failure of dye to enter the microvasculature; MBG 1: dye slowly enters but fails to exit the microvasculature; MBG 2: delayed entry and exit of dye from the microvasculature; MBG 3: normal entry and exit of dye from the microvasculature [8] .
Cardiac markers
Creatine kinase-MB (CK-MB) level in plasma was measured by immunoinhibition assay (Roche Hitachi 912, Germany) after arrival in emergency department and 8-12 hours after stent implantation. Serum troponin T concentration was measured with the cTnT assay from Roche Diagnostics (Mannheim, Germany). The lowest cTnT value to be measured reliably with this assay is 0,03 mg/L which is the lowest cTnT concentration that can be measured reproducibly with the between-run coefficient of variation of 10%.
Echocardiography evaluation
Left ventricular ejection fraction (LVEF) was calculated using Simpson's method from a two-dimensional trans-thoracic echocardiography evaluation [9] , performed at the second day of admission by dedicated personnel who were blinded to the treatment allocation.
Study end-points
The primary end-point (efficacy end-point) of this pilot study was the MACE rate at one-month follow-up, defined as the composite of all-cause death, reinfarction and clinicallyindicated target vessel revascularization (TVR). Secondary end-points (safety end-points) were stent thrombosis rate at 30-days and in-hospital bleeding event. Acute reperfusion parameters (TIMI flow and MBG), CK-MB level at 8-12 h after stenting, and LVEF were also assessed.
Two independent interventional cardiologists blinded to the treatment assignment of the patients, verified the assessment of TIMI flow and MBG. One month clinical follow-up was judged by an independent clinical event committee, blinded to the allocated stent type.
Definitions
Death was defined as all-cause death during 1-month follow-up. Re-infarction during follow-up was defined as a troponin T rise >0.03 μg/L with symptoms, or a second rise of troponin T >25% after recent MI in the presence of symptoms or the development of new Q waves on ECG [10, 11] . We defined TVR as a re-intervention driven by any lesion located in the IRA and included coronary artery bypass surgery involving the IRA [12] . Stent thrombosis criteria were according to the Academic Research Consortium classification [13] .
In-hospital bleeding criteria were according to the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) criteria [14] and described as: 1) Severe or lifethreatening bleeding: Intracranial bleeding or bleeding that causes substantial hemodynamic compromise requiring treatment; 2) Moderate bleeding: Bleeding that needs blood transfusion; 3) Minor bleeding: Other bleeding, neither requiring transfusion nor causing hemodynamic compromise.
Door-to-device time was defined as the time from patient arrival at the emergency department to the introduction of the first device, either a thrombus aspiration catheter or a balloon catheter into the IRA.
Procedural success was defined as completion of the planned procedure without associated in cath-lab major clinical complications (e.g., stroke, death or coronary artery perforation) [15] . The flow-chart of the study is presented in Figure 1 .
Statistical methods
Data were expressed as mean ± standard deviation for normally distributed continous variables. If data was distributed not normally, data was expressed as median and interquartile range. Continous variables were compared with Student's t-test or Mann-Whitney U-test. Chisquare test or Fisher`s exact test were used to compare categorical variables. Cox proportional hazards models were used to examine the association of stent type with the risk of clinical events (MACE).
As data regarding the use of EES in patients with eptifibatide treatment is lacking, we decided to enroll 150 patients (75 patients for each arm) in this pilot study before recruiting a larger population. Thus, study equivalence is not being tested.
A p-value of <0.05 was considered statistically significant. All statistical analyses were performed using a statistical package (SPSS version 17.0, SPSS Inc. Chicago, IL, USA).
Results
Baseline characteristics. Table 1 shows the baseline clinical characteristics of the patients in the two study groups. Most patients (85%) were male. The study groups were well-balanced in terms of baseline clinical characteristics and risk factors. Table 2 shows angiographic characteristics and procedural results. The two groups had similar anatomical and procedural characteristics. Thrombus aspiration was performed in 59% of the patients. PCI only on IRA was performed in the majority of the patients (93%). Procedural success was obtained in all patients (100%). Study end-points. During 1-month follow-up, MACE rates did not differ between the EES and the CoCr group (1.3% vs. 1.3%, p=1.0) ( Table 3) . A single case with probable stent thrombosis was observed in the CoCr group and none in the EES group. In-hospital bleeding event rates were similar in the EES and CoCr groups (5% vs. 9%, p=0.37) ( Table 4) . Acute reperfusion parameters. The EES and CoCr stent groups showed no significant differences in the achievement of final TIMI flow 2 or 3 (99% and 93%, p=0.21) and MBG 2 or 3 (72% and 77%, p=0.45) ( Table 4) .
MI= myocardial infarction, TVR= target vessel revascularization, HR= hazard ratio, CI= confidence interval. Table 5 ).
Discussion
The most important finding of this study is that the short-term (30 days) efficacy and safety of EES in acute STEMI patients (≤12 hours of onset) undergoing primary PCI with routine administration of intravenous eptifibatide are as good as the short-term efficacy and safety of the CoCr stent. These results contribute to the knowledge of efficacy and safety of DES in acute STEMI patients treated by primary PCI. 
Drug-eluting stent in acute STEMI
The use of first generation DES in the setting of primary PCI for acute STEMI remained controversial due to an increased risk of late stent thrombosis [16] , possibly related to delayed culprit vessel healing after DES implantation [17] and late acquired stent malapposition [18, 19] . Second generation DES have been developed to overcome the disadvantages related to first generation DES. Since several trials have shown an improvement of clinical outcomes during mid to long-term follow-up in patients who received second generation DES [20] [21] [22] , the use of DES have been widely used for off-label indications [23] . In acute STEMI, the use of EES has been investigated in several trials which showed favourable results compared with first generation DES [24, 25] or BMS [26] .
The ESC 2012 guidelines on the management of STEMI has qualified the use of DES for STEMI patients as class IIa recommendation [27] . However, data regarding efficacy and safety of second generation DES after primary PCI is still relatively scarce.
Our study showed that the use of EES after primary PCI is safe and does not increase the risk of MACE during 30-days follow-up. Furthermore, we did not find any stent thrombosis case in the EES group. Concordant with this result, a recent meta-analysis showed that EES was associated with a significant reduction in early (30 days) definite stent thrombosis (relative risk=0.28; p<0.0001) and early definite/ probable stent thrombosis (relative risk=0.54; p=0.005) compared with pooled paclitaxel, sirolimus and zotarolimus-eluting stents [28] .
Optimizing acute reperfusion treatment
Acute reperfusion parameters (TIMI flow and MBG) during primary PCI are important tools for immediate evaluation of a successful reperfusion treatment [29] . The use of routine GPI administration in combination with manual thrombus aspiration during primary PCI resulted in the achievement of final TIMI flow 2/3 and MBG grade 2/3 in 96% and 74% of the study population, respectively. These results strengthen the findings from Burzotta and colleagues who used the combination of GPI and thrombus aspiration during primary PCI and showed that the combination was associated with a lower mortality rate than GPI alone and thrombus aspiration alone [30] .
Administration of GPI and manual thrombus aspiration during primary PCI are recommended by the 2011 ACCF/AHA/SCAI guideline for PCI [31] and the 2012 ESC guideline on management of STEMI patients [27] (class IIa). However, routine pre-catheterization use of GPI has been indicated as a class IIb recommendation. In the EXAMINATION trial [26] , GPI (predominantly abciximab) was used in 52% of the study population, whereas in our study, eptifibatide was administered to all patients of the study population. Moreover, in our study, the similar MACE rate in the EES and CoCr groups can be explained by equal success to achieve reperfusion (final TIMI flow and MBG), which leads to similar CK-MB rises (p=0.29) and similar LVEF (p=0.21). The choice to use CK-MB level at 8-12 h after stenting was based on the fact that in patients with reperfused infarcts, serial CK-MB values in serum peak after 8.7 h and 12.6 h after onset of chest pain in patients with early and late reperfusion respectively [32] .
Several reasons may explain the low MACE rate and the absence of stent thrombosis associated with EES in our study. Firstly, it is postulated that stenting of a highly thrombotic lesion in a patient with acute STEMI may result in undersizing of the applied stent or incomplete stent apposition (which is known to be a predictor of stent thrombosis) [33] , probably due to the masking effect of thrombus in the vessel. In our study, the treatment with eptifibatide alone or in combination with manual thrombus aspiration was expected to dissolve thrombus and minimize distal embolization, which: 1) allows clear visualization of the true vessel diameter, 2) allows the choice of an appropriate stent size, and 3) eliminates early stent malapposition. Secondly, the maximal stent inflation pressures applied in the EES and CoCr groups were similar (Table 2) , which may indicate adequate stent deployment with well-opposed stent struts in the EES group. Thirdly, it is postulated that EES may have a rapid and complete endothelialization. Finally, the stent design of the Xience stents with thin struts, fractureresistant cobalt chromium stent struts, and low polymer and drug load [34] may also yield specific advantages.
Study limitation
The present study has several limitations. First, the observation period of this study was one month only, and to observe differences with respect to MACE rates and (very) late stent thrombosis rates between the two groups, we need longer follow-up periods. Second, this study was underpowered to detect benefits of EES in 1-month follow up, particularly when the MACE rate in the group of patients treated with the CoCr stent is very low. However, this is the first study that has investigated EES using routine administration of eptifibatide in STEMI patients and therefore this preliminary report may encourage the start of larger randomized trials.
Conclusion
The results of this pilot study indicate that, in a one-month observation period, the use of everolimus-eluting stents is as safe and effective as cobalt chromium stents in patients with acute STEMI undergoing primary PCI with routine administration of intravenous eptifibatide. Future trials with much larger sample size and longer follow-up are necessary to confirm these results.
